Effectiveness of Vortioxetine for the Treatment of Emotional Blunting in Patients with Major Depressive Disorder Experiencing Inadequate Response to SSRI/SNRI Monotherapy in Spain: Results from the COMPLETE Study.
Michael Cronquist ChristensenFrancesca CanellasHenrik LoftÁngel L MontejoPublished in: Neuropsychiatric disease and treatment (2024)
In this study investigating the effectiveness of vortioxetine in Spanish patients with MDD who experienced inadequate response and emotional blunting on SSRI/SNRI monotherapy, significant improvements in emotional blunting, core depressive symptoms (including anhedonia), sleep duration, motivation and energy, cognitive performance, and overall patient functioning were observed during the 8 weeks of treatment. Two-thirds of patients no longer reported emotional blunting and over half were in remission from their depressive symptoms at week 8.
Keyphrases
- major depressive disorder
- depressive symptoms
- bipolar disorder
- combination therapy
- randomized controlled trial
- systematic review
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- social support
- clinical trial
- rheumatoid arthritis
- case report
- prognostic factors
- disease activity
- patient reported outcomes
- systemic lupus erythematosus
- patient reported